Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

BACKGROUND: Isatuximab (Isa), an anti‐CD38 monoclonal antibody, and carfilzomib (K), a next‐generation proteasome inhibitor (PI), both have potent single‐agent activity in relapsed and refractory multiple myeloma (RRMM). METHODS: This phase 1b study evaluated the combination of Isa and K in 33 patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Martin, Thomas G., Shah, Nina, Richter, Joshua, Vesole, David H., Wong, Sandy W., Huang, Chiung‐Yu, Madduri, Deepu, Jagannath, Sundar, Siegel, David S., Biran, Noa, Wolf, Jeffrey L., Parekh, Samir, Cho, Hearn J., Munster, Pamela, Richard, Shambavi, Ziti‐Ljajic, Samira, Chari, Ajai
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8252002/
https://ncbi.nlm.nih.gov/pubmed/33735504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33448
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados